Cytek Biosciences Inc (CTKB)
Profitability ratios
Return on sales
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | |
|---|---|---|---|
| Gross profit margin | 56.69% | 3,407.83% | 3,628.79% |
| Operating profit margin | -14.43% | -60.88% | 419.85% |
| Pretax margin | -8.14% | 42.52% | 272.26% |
| Net profit margin | -6.29% | 83.83% | 138.79% |
Cytek Biosciences Inc's profitability ratios show significant fluctuations over the past three years. The gross profit margin has been relatively stable, standing at 56.69% in 2023, which indicates that the company retains a good portion of its revenue after deducting the cost of goods sold. However, the operating profit margin has been negative in 2023 and 2022, suggesting that the company's operating expenses are high compared to its revenue, leading to operating losses.
The pretax margin also shows a negative trend in 2023 and 2022, indicating that Cytek Biosciences Inc's profitability before accounting for taxes has been declining. The net profit margin has decreased substantially from 2021 to 2023, indicating that the company's net income as a percentage of revenue has decreased over time.
Overall, Cytek Biosciences Inc appears to be facing challenges in maintaining profitability, with negative operating and pretax margins in recent years. The company may need to focus on controlling operating expenses and improving operational efficiency to enhance its profitability in the future.
Return on investment
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | |
|---|---|---|---|
| Operating return on assets (Operating ROA) | -5.63% | -0.35% | 1.98% |
| Return on assets (ROA) | -2.46% | 0.48% | 0.65% |
| Return on total capital | -3.47% | 0.90% | 1.89% |
| Return on equity (ROE) | -3.09% | 0.58% | 0.75% |
Cytek Biosciences Inc's profitability ratios have shown a declining trend over the past three years.
1. Operating Return on Assets (Operating ROA): This ratio indicates the efficiency of the company in generating operating profits from its total assets. Cytek Biosciences Inc's Operating ROA has decreased significantly from 1.98% in 2021 to -5.63% in 2023, reflecting a sharp decline in operational profitability.
2. Return on Assets (ROA): ROA signifies the company's overall ability to generate profits from its total assets. Cytek Biosciences Inc's ROA has also shown a negative trend, dropping from 0.65% in 2021 to -2.46% in 2023, indicating decreasing profitability relative to its asset base.
3. Return on Total Capital: This ratio measures the company's efficiency in generating returns from both debt and equity capital. Cytek Biosciences Inc experienced a notable decrease in Return on Total Capital, falling from 1.89% in 2021 to -3.47% in 2023, suggesting a declining ability to generate returns on its total invested capital.
4. Return on Equity (ROE): ROE evaluates the company's profitability from the perspective of its shareholders. Cytek Biosciences Inc's ROE has also declined from 0.75% in 2021 to -3.09% in 2023, indicating a decrease in profitability relative to shareholder equity.
Overall, Cytek Biosciences Inc's profitability ratios reflect a concerning downward trend, highlighting challenges in generating profits from its assets, capital, and equity over the past three years. Management may need to review operational efficiency and strategic planning to improve profitability in the future.